No Data
No Data
Express News | Actuate Completes Enrollment In Phase 2 Trial Of Elraglusib Plus FOLFIRINOX And Losartan
Actuate Announces Completion of Enrollment in a Phase 2 Trial of Elraglusib in Combination With FOLFIRINOX and Losartan in Patients With Previously Untreated Metastatic Pancreatic Cancer
Is Actuate Therapeutics (NASDAQ:ACTU) In A Good Position To Deliver On Growth Plans?
Actuate Therapeutics to Participate in Upcoming Investor Conferences in February
Top Premarket Gainers
12 Health Care Stocks Moving In Friday's Pre-Market Session